© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Funding from Daiichi Sankyo; Content Developed Independently by OncLive.
January 25th 2022
Rachel E. Factor, MD, MS, discusses the lack of standardization with biomarker testing in breast and gastrointestinal cancers.
Rondell P. Graham, MBBS, discusses the role of the pathologist in biomarker testing for patients with breast and gastrointestinal cancers.
Aatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.
February 25th 2022
This publication provides a summary of key stakeholder insights on methodological limitations and analytical factors to consider pertaining to biomarker testing for HER2+ across cancer types, with particular emphasis on the role of the pathologist in the multidisciplinary management of cancer.